GeoVax Labs, Inc. (GOVX)

Market Cap	13.98M
Revenue (ttm)	5.59M
Net Income (ttm)	-24.50M
Shares Out	13.84M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,595
Open	1.020
Previous Close	1.020
Day's Range	0.970 - 1.020
52-Week Range	0.730 - 11.180
Beta	3.49
Analysts	Strong Buy
Price Target	12.40 (+1,127.72%)
Earnings Date	May 1, 2025

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vacc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: GOVX
• Website: https://www.geovax.com

Analyst Forecast

According to 5 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price forecast is $12.4, which is an increase of 1,127.72% from the latest price.

Price Target

$12.4

(1,127.72% upside)

Analyst Consensus: Strong Buy